Teduglutide in the treatment of short bowel syndrome in Crohn’s disease

Česká verzia

Authors: Gombošová L. ¹; Krivuš J. ²
Authors place of work: I. interná klinika LF UPJŠ a UN L. Pasteura Košice 2 I. interná klinika JLF UK a UN Martin ¹
Published in the journal: Gastroent Hepatol 2021; 75(3): 252-256
Category:
doi: https://doi.org/10.48095/ccgh2021252

Summary

Crohn’s disease is an immune-mediated chronic progressive inflammation of the gastrointestinal tract. Many patients require repeated surgeries, 8.6% may develop short bowel syndrome. Short bowel syndrome is a rare diagnosis. Home parenteral nutrition via long-term central venous catheter is the standard of care. Teduglutide a is recombinant analogue of intestinal glucagon-like peptide 2 (GLP2). It is approved for treatment of the short bowel syndrome, it induces intestinal adaptation and increases its resorption capacity. The effect of the treatment is to reduce the volume of parenteral substitution to complete weaning from PN and induction of intestinal autonomy. The review article deals with short bowel syndrome in Crohn’s disease treated with GLP2 analogue

Keywords:

short bowel syndrome – teduglutide – glucagon like peptide 2 – Crohn’s disease – intestinal failure – home parenteral nutrition

Zdroje

1. Pironi L, Arends J, Baxter J et al. Home artificial nutrition and chronic intestinal failure., Acute intestinal failure special interest groups of ESPEN. Clin Nutr 2015; 34(2): 171–180. doi: 10.1016/ j.clnu.2014.08.017.

2. DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and the short bowel syndrome: Part 1. Am J Gastroenterol 2004; 99: 1386–1395. doi: 10.1111/ j.1572-0241.2004.30345.x.

3. Pironi L. Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature. J Parenter Enteral Nutr 2020; 44(6): 968–978. doi: 10.1002/ jpen.1757.

4. Massironi S, Cavalcoli F, Rausa E et al. Understanding short bowel syndrome: Current status and future perspectives. Dig Liv Dis 2020; 52: 253–261. doi: 10.1016/ j.dld.2019.11.013.

5. Kochar B, Long MD, Shelton E et al. Safety and efficacy of teduglutide (Gattex) in patients with Crohn’s disease and need for parenteral support due to short bowel syndrome associated intestinal failure. J Clin Gastroenterol 2017; 51(6): 508–511. doi: 10.1097/ MCG.0000000000000604.

6. Limetkai BN, Parian AM, Shah ND et al. Short bowel syndrome and intestinal failure in Crohn‘s disease. Inflamm Bowel Dis 2016; 22(5): 1209––1218. doi: 10.1097/ MIB.0000000000000698.

7. Watanabe K, Sasaki I, Fukushima K et al. Long-term incidence and characteristics of intestinal failure in Crohn‘s disease: a multicenter study. J Gastroenterol 2014; 49(2): 231–238. doi: 10.1007/ s00535-013-0797-y.

8. Watanabe Y, Miyoshi N, Fujino S et al. Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn‘s Disease. Dig Dis Sci 2019; 64(8): 2280–2285. doi: 10.1007/ s10620-019-05553-2.

9. Soop M, Khan M, Nixon E et al. Causes and prognosis of intestinal failure in Crohn’s disease: an 18-year experience from a national centre. Journal of Crohn‘s and Colitis 2020; 1558–1564. doi: 10.1093/ ecco-jcc/ jjaa060.

10. Forbes A, Escher J, Hébuterne X et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017; 36: 321–347. doi: 10.1016/ j.clnu.2016.12.027.

11. FDA Approval. Gattex, teduglutide. 2012 [online]. Available from: https:/ / www.accessdata.fda.gov/ drugsatfda_docs/ nda/ 2012/ 203441 Orig1s000TOC.cfm.

12. Ministerstvo zdravotníctva Slovenskej republiky. Zoznam kategorizovaných liekov 1. 11. 2020–30. 11. 2020 [online]. Available from: https:/ / www.health.gov.sk/ Clanok?lieky202011.

13. Jeppesen PB. The long road to the development of effective therapies for the short gut syndrome: a personal perspective. Dig Dis Sci 2019; 64: 2717–2735. doi: 10.1007/ s10620-019-05779-0.

14. Tappenden KA. Intestinal adaptation following resection. JPEN J Parenter Enteral Nutr 2014; 38: 23–31. doi: 10.1177/ 0148607114 525210.

15. Reiner J, Berlin P, Wobar J et al. Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufciency. Dig Dis Sci 2020; 65: 3521–3537. doi: 10.1007/ s10620-020-06140-6.

16. Borhgini R, Caronna R, Donato G et al. Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition – dependent Crohn‘s disease. Turk J Gastroenterol 2017; 28: 73–74. doi: 10.5152/ tjg.2016.0587.

17. Borghini R, Caronna R, Donato G et al. GLP-2 analog Teduglutide in active Crohn’s disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives. Dig Liv Dis 2020; 52: 686–687. doi: 10.1016/ j.dld.2020.03.019.

18. Costa BP, Goncalves AC, Abrantes AM et al. Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats. Acta Cir Bras 2017; 32(8): 648–661. doi: 10.1590/ s0102-865020170080000007.

19. Jeppesen PB, Gabe SM, Seidner DL et al. Factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure. Gastroenterology 2018; 154: 874–885. doi: 10.1053/ j.gastro.2017.11.023.

20. O’Keefe S, Pape UF, Lee HM et al. Subanalysis of teduglutide efficacy and safety data from patients with Crohn’s disease and ulcerative colitis in the STEPS Study. Am J Gastroenterol 2016; 111(Suppl): S265.

21. Revestive (teduglutid). Súhrn charakteristických vlastností lieku. [online]. Available from: https:/ / www.ema.europa.eu/ en/ documents/ all-authorised-presentations/ revestive-epar-all-authorised-presentations_sk.pdf.

22. Novák F. Teduglutid, analog glukagonu podobného peptidu-2 (REVESTIVE), v léčbě syndromu krátkeho střeva se závislostí na domácí parenterální výživě. Gastroent Hepatol 2021; 75(2): 170–172. doi 10.48095/ ccgh20211170.

23. Seidner DL, Gabe SM, Lee HM et al. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. J Parenter Enteral Nutr 2012; 44(4): 697–702. doi: 10.1002/ jpen.1687.

24. Schoeler M, Klag T, Wendler J et al. GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting. Ther Adv Gastroenterol 2018; 11: 1–11. doi: 10.1177/ 1756284818793343.

25. Tee ChT, Wallis K, Gabe SM. Emerging treatment options for short bowel syndrome: potential role of teduglutide. Clin Exp Gastroenterol 2011; 4: 189–196. doi: 10.2147/ CEG.S13906.

26. Pape UF, Iyer KR, Jeppesen PB et al. Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. Ther Adv Gastroenterol 2020; Vol. 13: 1–18. doi: 10.1177/ 1756284820905766.

27. Borghini R, Caronna R, Corazziari ES et al. Further improvement after 24-month treatment with teduglutide in a patient with active Crohn’s disease and short bowel syndrome. Turk J Gastroenterol 2018; 29: 249–250. doi: 10.5152/ tjg.2018.17596.

28. Barberio B, Sturniolo GC, D’Inca R et al. Efficacy of teduglutide in a patient with Crohn’s disease and short bowel syndrome on enteral nutrition: let’s start to think out of the box. Gastroenterology Report 2019; 7(6): 459–460. doi: 10.1093/ gastro/ goz030.

29. Micic D, Wall E, Rubin D et al. Teduglutide Use for Intestinal Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22(Suppl): S35.

30. Chiplunker A, Ha Ch, Paski S. Teduglutide use in Crohn’s disease: a case series. Disease Complications 2020; 158(3): Suppl S37, P108. doi: 10.1053/ j.gastro.2019.11.113.

31. Draiweesh SA, Ma Ch, Gregor JC et al. Teduglutide in patients with active Crohn’s disease and short bowel syndrome. Inflamm Bowel Dis 2019; 25(9): 109. doi: 10.1093/ ibd/ izz087.